Preliminary Probe of Serum 2019-NCoV IgM and IgG Antibodies for Diagnosis of Novel Coronavirus Pneumonia%J Chunghua Medical Journal

Objective: To analyze the clinical value of serum 2019 novel coronavirus (2019-NCoV) immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies in diagnosing novel coronavirus pneumonia (NCP). Method: Case control study. Collected from January to February 2020 at the First Affiliated Hospital of Hunan University of Chinese Medicine and the First Hospital of Xiamen University A total of 116 confirmed patients in the disease group, the non-NCP population contained 84 patients and 50 health examiners, a total of 134 cases in the control group. Collect serum specimens from all study subjects. A fully automated chemoluminescent immunoanalyzer detects 2019-NCoV IgM and IgG antibody concentrations in serum. The sensitivity and specificity of 2019-NCoV IgM, IgG antibody monomial test and its combined detection were compared using the ≈ 2 test, and the comparison of IgM, IgG antibody positivity and concentration before and after NCP patients 2019-NCoV nucleic acid transpubic acid, respectively. The trend of change in concentration of 2019-NCoV antibodies in patients with NCP is used by Wilcoxon rank and test. Results: The sensitivity of 2019-NCoV IgG (90.5%, 105/116) was higher than 2019-NCoV IgM (75.9%, 88/116), the difference was statistically significant (≈ 2=8.91, P<0.05); the specificity of 2019-NCoV IgG (99.3%, 133/134) was higher than 2019- NCoV IgM (94.0%, 126/134), the difference is statistically significant (2=5.63, P<0.05). The sensitivity after 2019-NCoV IgM combined IgG (89.7%, 87/97) is higher than 2019-NCoV IgM, the difference is statistically significant (≈ 2=6.89, P<0.05); the specificity after 2019-NCoV IgG (100%, 125/125) is higher than 2019-NCoV IgM, The difference is statistically significant (≈ 2=7.70, P<0.05). Serum 2019-NCoV IgM antibody positive rate (9/17) and concentration [13.0 (4.9, 24.7) AU/mL] after 2019-NCoV nucleic acid transpubic acid transpubic positive rate (15/17) and concentration [29.5 (14.0, 61.3) AU/mL] (≈ 2=5.10, Z=- 3.195, P both <0.05). In the course of NCP, the patient serum specimen is retained from day 1 of diagnosis to three days at intervals. 1st 2019-NCoV IgM and IgG antibody concentrations [19.4 (12.4, 63.7) AU/mL, 105.8 (74.8, 126.1) AU/mL, respectively] were both significantly higher than the 2nd concentration [15.8 (7.1, 40.3) AU/mL, 80.5 (66.7, 105.9) AU/mL, respectively] (Z 2.897, -3.179, P both <0.05). Conclusion: 2019-NCoV IgG antibodies have good application value for diagnosing NCP; 2019-NCoV IgM antibody concentration has some association with 2019-NCoV nucleic acid detection; 2019-NCoV IgM and IgG antibodies combined with 2019-NCoV nucleic acid detection may be the best laboratory indicator for diagnosing NCP at present.